Enhanced DNA damage-induced p53 peptide phosphorylation and cell-cycle arrest in Sjögren's syndrome cells

European Journal of Clinical Investigation

Volumn 32, Issue 6, 2002, Pages 458-465

  Henriksson, G ^a,b   Brant, M ^a,b   Sallmyr, A ^a,b   Fukushima, S ^a,b   Manthorpe, R ^a,b   Bredberg, A ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Autoimmunity; DNA damage response; DNA dependent protein kinase; Sj gren's syndrome

Indexed keywords

AUTOANTIBODY; DNA; DNA DEPENDENT PROTEIN KINASE; PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL KINETICS; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MALE; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; SJOEGREN SYNDROME; STRESS; T LYMPHOCYTE;

ADULT; AGED; AUTOANTIBODIES; CELL CYCLE; CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; FEMALE; GAMMA RAYS; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PEPTIDES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SJOGREN'S SYNDROME; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036997936     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00997.x     Document Type: Article

References (41)

1. Oxholm P, Asmussen K. Primary Sjögren's syndrome: the challenge for classification of disease manifestations. J Intern Med 1996;239:467-74.
2. Manthorpe R, Frost-Larsen K, Isager H, Prause JU. Sjögren's syndrome. A review with emphasis on immunological features. Allergy 1981;36:139-53.
3. Fox RI, Kang H-I. Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 1997;149:7-11.
4. Price EJ, Venables PJW. The etiopathogenesis of Sjögren's syndrome. Semin Arthritis Rheum 1995;25:117-33.
5. Tan EM. Interactions between autoimmunity and molecular and cell biology. Bridges between clinical and basic sciences. J Clin Invest 1989;84:1-6.
6. Von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
7. Suwa A, Hirakata M, Takeda Y, Okano Y, Mimori T, Inada S et al. Autoantibodies to DNA-dependent protein kinase. Probes for the catalytic subunit. J Clin Invest 1996;97:1417-21.
8. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-8.
9. Fox RI, Fong S, Chen PP, Kipps TJ. Autoantibody production in Sjögren's syndrome: a hypothesis regarding defects in somatic diversification of germ line encoded genes. In Vivo 1988;2:47-56.
10. Henriksson G, Sandor Z, Aponyi I, Manthorpe R, Bredberg A. A reduced level of multiple mutation in a shuttle vector passaged in Sjögren's syndrome cells. Mutat Res 1994;324:103-10.
11. Henriksson G, Brant M, Sandor Z, Manthorpe R, Bredberg A. Sjögren's syndrome: lymphoma predisposition coupled with a reduced frequency of t(19; 18) translocations in blood lymphocytes. Molec Carcino 1999;24:226-31.
12. 6-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma. Ann Rheum Dis 1995;54:229-32.
13. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993;52:659-66.
14. Yaneva M, Arnett FC. Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin Exp Immunol 1989;76:366-72.
15. Smith GCM, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999;13:916-34.
16. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-26.
17. Lakin ND, Jackson SP. Regulation of p53: in response to DNA damage. Oncogene 1999;18:7644-55.
18. Sionov RV, Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 1999;18:6145-57.
19. Lavasani S, Henriksson G, Brant M, Henriksson A, Radulic M, Manthorpe Ret al. Abnormal DNA-damage inducible protein in cells from Sjögren's syndrome patients. J Autoimmun 1998;11:363-9.
20. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
21. Manthorpe R, Oxholm P, Prause JU, Schiødt M. The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol 1986;61 (Suppl.):19-21.
22. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res1983;11:1475-89.
23. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosporylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992;12:5041-9.
24. Sallmyr A, Henriksson G, Fukushima S, Bredberg A. Ku protein in human T and B lymphocytes: full length functional form and signs of degradation. Biochim Biophys Acta 2001;14740:1-8.
25. Kirtava Z, Blomberg J, Bredberg A, Henriksson G, Jacobsson L, Manthorpe R. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995;13:609-16.
26. Snedecor GW, Cochran WG.Statistical Methods. 6th ed. Ames, IA: Iowa State University Press;1967.
27. Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP. DNA-dependent protein kinase activity is absent in xrs-6 cells: implications for site-specific recombination and DNA double-strand break repair. Proc Natl Acad Sci USA 1995;92:320-4.
28. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
29. Friedberg EC, Walker GC, Siede W. Regulatory responses to DNA-damaging agents in eukaryotic cells: cell cycle arrest as a response to DNA damage. In: DNA Repair and Mutagenesis. Washington DC, USA: ASM Press;1995.pp.607-18.
30. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997;15:177-202.
31. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
32. Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakayuchi Ket al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
33. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson Ket al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998;20:398-400.
34. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh S-Y et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-7.
35. Shieh S-Y, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34.
36. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83:237-45.
37. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
38. Zeher M, Szodoray P, Gyimesi E, Szondy Z. Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome. Arthritis Rheum 1999;42:1673-81.
39. Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sjögren's syndrome. Novel p53 mutations. Arthritis Rheum 1999;42:1466-72.
40. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143-51.
41. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997;94:10895-900.